M&A
Enzymaster’s Sanming Minhe Acquisition Increases Production Capacity by 50% to Keep Pace with Rapidly Growing Demand
Enzymaster
PR-M01-22-14Jan 20, 2022
Drug Development
A New Approach for Diseases Associated with BH4-Dependent Enzymatic Pathways
Jonathan Reis, Ph.D.
PAP-Q1-20-CL-011Mar 19, 2020
Chiral Synthesis
Applying Enzymatic Synthesis for Chiral Molecules
Juliette Martin, Ph.D.; Sergio Kreimerman, Ph.D.
Seqens
PAP-Q2-2019-CL-029May 24, 2019
Launch
New England Biolabs® Launches NEBNext® Enzymatic Methyl-seq (EM-seq™) for Bisulfite-Free Methylation Analysis
New England Biolabs
PR-M05-19-NI-003May 01, 2019
FDA Fast Track
Enzyvant's Investigational Farber Disease Enzyme Replacement Therapy, RVT-801, Receives FDA Fast Track and Rare Pediatric Disease Designations
Enzyvant
PR-M03-19-NI-073Mar 26, 2019
Cell and Gene Therapy
BridgeBio Pharma Launches CoA Therapeutics to Target Coenzyme-A for Rare Genetic Disorders
BridgeBio Pharma
PR-M06-18-NI-052Jun 15, 2018
Drug Discovery
RNA-Modifying Proteins May Provide New Drug Targets
Guy Tiene
Nice Insight
PAO-M05-18-NI-018May 24, 2018
Acquisition
Almac Expands Analytical Services with BioClin Laboratories Acquisition
Nice Insight
PAO-M11-17-NI-033Nov 21, 2017